The novel bacteriocin romsacin from Staphylococcus haemolyticus inhibits Gram-positive WHO priority pathogens

Microbiol Spectr. 2023 Dec 12;11(6):e0086923. doi: 10.1128/spectrum.00869-23. Epub 2023 Oct 31.

Abstract

Bacteria produce bacteriocins to inhibit growth of other bacterial species. We have studied the antimicrobial activity of a new bacteriocin produced by the skin bacterium S. haemolyticus. The bacteriocin is effective against several types of Gram-positive bacteria, including highly virulent and antibiotic-resistant strains such as Staphylococcus aureus and Enterococcus faecium. Effective antimicrobials are important for the treatment of infections and the success of major surgery and chemotherapy. Bacteriocins can be part of the solution to the global concern of antimicrobial resistance.

Keywords: AMR; CoNS; Staphylococcus haemolyticus; WHO priority pathogens; antimicrobial resistance; bacteriocin; biofilm; lanthipeptides; lantibiotics; romsacin.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents*
  • Bacteriocins* / pharmacology
  • Staphylococcus haemolyticus
  • World Health Organization

Substances

  • Bacteriocins
  • Anti-Bacterial Agents
  • Anti-Infective Agents